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Abstract
Prostaglandin E2 (PGE2) and prostaglandin I2 (PGI2) are major inflammatory mediators that play
important roles in pain sensation and hyperalgesia. The role of their receptors (EP and IP,
respectively) in inflammation has been well documented, although the EP receptor subtypes
involved in this process and the underlying cellular mechanisms remain to be elucidated. The
capsaicin receptor TRPV1 is a nonselective cation channel expressed in sensory neurons and
activated by various noxious stimuli. TRPV1 has been reported to be critical for inflammatory pain
mediated through PKA- and PKC-dependent pathways. PGE2 or PGI2increased or sensitized
TRPV1 responses through EP1 or IP receptors, respectively predominantly in a PKC-dependent
manner in both HEK293 cells expressing TRPV1 and mouse DRG neurons. In the presence of PGE2
or PGI2, the temperature threshold for TRPV1 activation was reduced below 35°C, so that
temperatures near body temperature are sufficient to activate TRPV1. A PKA-dependent pathway
was also involved in the potentiation of TRPV1 through EP4 and IP receptors upon exposure to
PGE2 and PGI2, respectively. Both PGE2-induced thermal hyperalgesia and inflammatory nociceptive
responses were diminished in TRPV1-deficient mice and EP1-deficient mice. IP receptor
involvement was also demonstrated using TRPV1-deficient mice and IP-deficient mice. Thus, the
potentiation or sensitization of TRPV1 activity through EP1 or IP activation might be one important
mechanism underlying the peripheral nociceptive actions of PGE2 or PGI2.
Background
Tissue damage and inflammation produce an array of
chemical mediators such as ATP, bradykinin, prostanoids,
protons, cytokines and peptides including substance P
that can excite or sensitize nociceptors to elicit pain at the
site of injury. Among them prostanoids were shown to
influence inflammation, and their administration was
found to reproduce the major signs of inflammation
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including augmented pain [1]. Prostaglandin E2 (PGE2)
and prostaglandin I2 (PGI2) are the products of arachi-
donic acid metabolism through the cyclooxygenase path-
way. In addition to numerous other physiological actions
in vivo, previous studies have indicated important roles for
PGE2 in nociception and inflammation [2,3]. PGE2 is gen-
erated in most cells in response to mechanical, thermal or
chemical injury and inflammatory insult, resulting in sen-
sitization or direct activation of nearby sensory nerve end-
ings. Analgesic effects of non-steroidal anti-inflammatory
drugs (NSAIDs) are attributed predominantly to inhibi-
tion of prostaglandin synthesis. Prostaglandins act upon a
family of pharmacologically distinct prostanoid receptors
including EP1, EP2, EP3, EP4 and IP that activate several
different G protein-coupled signaling pathways [2,4,5].
Primary sensory neurons in dorsal root ganglion (DRG)
are known to express mRNAs encoding several prostanoid
receptor subtypes, IP, EP1, EP3 and EP4 [6,7]. The role of IP
in inflammation has been clearly shown by the analysis of
IP-deficient mice, although the underlying cellular mech-
anisms still remain to be elucidated [8]. In contrast, the
potential involvement of EP receptors other than IP in
inflammation and pain generation has not been well
studied, although some earlier studies have suggested that
prostanoids contribute to the development of pain
through EP receptors [9,10].
The capsaicin receptor TRPV1 is a non-selective cation
channel expressed predominantly in unmyelinated C-fib-
ers [11]. TRPV1 is activated not only by capsaicin, but also
by protons or heat (with a threshold > ~43°C), both of
which cause pain in vivo [11-13]. A prominent role of
TRPV1 in nociception has been demonstrated in studies
of TRPV1-deficient mice [14,15].
Recently, we reported that inflammatory mediators such
as ATP, bradykinin and trypsin or tryptase potentiate
TRPV1 activity in a PKC-dependent manner [16-18], and
identified two target serine residues in TRPV1 as substrates
for PKC-dependent phosphorylation [19]. On the other
hand, there are several reports showing that a PKA signal-
ing pathway mediates PGE2-induced potentiation of cap-
saicin-evoked responses in rat sensory neurons [20-22].
Therefore, we examined the effects of PGE2 and PGI2 on
TRPV1 activity. Surprisingly, we found the functional
interaction of TRPV1 with PGE2 or PGI2 occurs mainly
through a PKC-dependent pathway at both cellular and
behavioral levels.
Results
Functional interaction between TRPV1 and PGE2
In order to examine the possibility that TRPV1 is involved
in PGE2-induced hyperalgesia in vivo, we performed a
behavioral analysis using wild type and TRPV1-deficient
(TRPV1-/-) mice. PGE2 (500 pmol/20 µL) produced a sig-
nificant reduction in paw withdrawal latency in response
to radiant heat (thermal hyperalgesia) at 5 to 90 min fol-
lowing intraplantar injection in wild type mice (Figure
1A). On the other hand, the PGE2-induced thermal hyper-
algesia was almost completely abolished in TRPV1-/- mice,
suggesting a functional interaction between PGE2  and
TRPV1 (Figure 1A), consistent with a previous report that
capsaicin-ablation of primary afferent neurons prevents
PGE2-induced thermal hyperalgesia [23]. We next exam-
ined the interaction between PGE2 and TRPV1 in mouse
DRG neurons using the patch-clamp technique. Capsaicin
(100 nM) evoked small inward currents in DRG neurons.
The capsaicin-evoked currents were significantly potenti-
ated by 1.5 min pretreatment with PGE2 (1µM) in 19 of 23
cells as previously reported [21] (Figure 1C) (3.36 ± 0.55
fold increase, n = 23 for PGE2 (+); 0.78 ± 0.08 fold for
PGE2 (-) (Cont.), n = 5, p < 0.05). Because it has been sug-
gested that a PKA-dependent pathway is predominantly
involved in the PGE2-induced potentiation of capsaicin-
activated currents in rat DRG neurons [21], we examined
the potential involvement of such a mechanism both in
mouse DRG neurons and human embryonic kidney-
derived HEK293 cells expressing TRPV1. No potentiation
of the capsaicin-activated current responses was observed
in DRG neurons treated with a mixture of forskolin (FSK,
10 µM), 3-isobutyl-1-methylxanthine (IBMX, 1 mM) and
dibutyryl-cAMP (dbcAMP, 3 mM) for the same time
period (1.5 min) (1.15 ± 0.20 fold increase, n = 9)
although a significant increase in cAMP level was con-
firmed during such the treatment (Figures 1B and 1C).
When we treated cells longer (6.5 min), 7 out of 14 cells
showed increase of capsaicin-activated currents (2.15 ±
0.77 fold increase, n = 14, p = 0.28) (Figure 1C). In
HEK293 cells, two different short (1.5 min) treatments to
activate PKA produced no potentiation (Figure 1D) (treat-
ment with a mixture of FSK, IBMX and dbcAMP in cells
expressing TRPV1, 1.20 ± 0.19 fold increase, n = 11, and
treatment with isoproterenol (Isop.) in cells expressing
both TRPV1 and mouse β1-adrenergic receptors (β1-ADR),
0.83 ± 0.12 fold increase, n = 4) although a significant
increase in cAMP level was confirmed following both
treatments in HEK293 cells (Figure 1B). We also exam-
ined the effects of long treatment (6.5 min) with a mixture
of FSK, IBMX and dbcAMP. This treatment caused signifi-
cant potentiation of capsaicin-activated currents (2.39 ±
0.60 fold increase, n = 7, p < 0.05) (Figure 1D). These
results suggest that both PKA-dependent and -independ-
ent pathways are involved in the potentiation of the cap-
saicin-activated currents by PGE2, that it takes longer to
cause potentiation of capsaicin-activated currents through
a PKA-dependent pathway, and that the PKA-independent
pathway is predominantly involved under the short treat-
ment conditions. Indeed, it has been reported that capsa-
icin-activated currents were not increased upon FSK/IBMXMolecular Pain 2005, 1:3 http://www.molecularpain.com/content/1/1/3
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Physiological interaction of PGE2 with TRPV1 in mice Figure 1
Physiological interaction of PGE2 with TRPV1 in mice. (A) PGE2-induced thermal hyperalgesia in TRPV1+/+ mice (❍ , n = 6) or 
TRPV1-/- mice (Њ, n = 6). Reduction of paw withdrawal latency (thermal hyperalgesia) by intraplantar PGE2 (500 pmol/ 20 µL) 
injection was significantly diminished in TRPV1-/- mice. * p < 0.05, ** p < 0.01 vs. TRPV1+/+ mice. (B) Intracellular cAMP levels in 
mouse DRG neurons or HEK293 cells treated with a mixture of forskolin (FSK, 10 µM), IBMX (1 mM) and dibutyryl cAMP 
(dbcAMP, 3 mM), or PGE2 (1 µM) or isoproterenol (Isop., 10 µM). *, # p < 0.05 vs. Cont., **, ## p < 0.01 vs. Cont. (C) Repre-
sentative traces of potentiation of capsaicin (100 nM)-activated current by extracellular PGE2 (1 µM, 1.5 min) or a mixture of 
FSK(10 µM), IBMX (1 mM) and dbcAMP (3 mM) (6.5 min) in mouse DRG neurons. Currents were normalized to values 
induced by first capsaicin application in the absence of additives (bar graph). Capsaicin was reapplied 1.5 or 6.5 min after expo-
sure to bath solution with additives. Numbers in parenthesis indicate cells tested. * p < 0.05 vs. Cont. Holding potential (Vh): -
60 mV. (D) Long (6.5 min) but not short (1.5 min) activation of PKA pathway has effect on TRPV1 responses in HEK293 cells. 
FSK (10 µM), IBMX (1 mM) and dbcAMP (3 mM) were applied to cells expressing rat TRPV1. Isop. (10 µM) was applied to cells 
expressing both rat TRPV1 and β1-adrenergic receptors (β1-ADR). Numbers in parenthesis indicate cells tested. Vh: -60 mV. * 
p < 0.05 vs Cont.Molecular Pain 2005, 1:3 http://www.molecularpain.com/content/1/1/3
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or 8-bromo-cAMP (8-Br-cAMP)/IBMX treatment in Xeno-
pus oocytes expressing TRPV1, or treatment with isoprot-
erenol in oocytes expressing both TRPV1 and β1-ADR
[24].
PGE2 increases TRPV1 activity through EP1 receptors
To explore the mechanism underlying the PKA-independ-
ent PGE2 (1.5 min)-induced potentiation of the capsaicin-
evoked responses observed in DRG neurons, we first
examine the effects of PGE2 on capsaicin-activated cur-
rents in HEK293 cells expressing TRPV1 and each EP
receptor. PGE2 (1 µM, 1.5 min) caused a robust increase in
the magnitude of low dose (20 nM) capsaicin-activated
currents in HEK293 cells co-expressing TRPV1 with EP1
(0.90 ± 0.04 fold increase, n = 9 for control (Cont.); 4.60
± 1.03 fold, n = 17 for PGE2, p < 0.05) (Figures 2A and
2B). This increase lasted more than three minutes, as we
previously reported for PAR-2 (proteinase activated recep-
tor 2)-mediated potentiation of TRPV1 activity [16]. In
contrast, no such potentiation was detected in cells
expressing TRPV1 with other EP receptor subtypes (0.91 ±
0.09 fold increase, n = 7; 0.77 ± 0.13, n = 9; 0.72 ± 0.24, n
= 5; 0.98 ± 0.18, n = 7; 0.89 ± 0.15, n = 9 for EP2, EP3α,
EP3β, EP3γ or EP4, respectively) (Figure 2B). Protracted (6.5
min) treatment with PGE2 caused a significant increase in
capsaicin-activated currents in cells expressing TRPV1 and
EP4, a phenomenon like that observed following treat-
ment with a mixture of FSK, IBMX and dbcAMP (3.03 ±
0.48 fold increase, n = 6, p < 0.05 vs. Cont.) (Figure 2B),
suggesting that the EP4 receptor, known to be expressed in
DRG and coupled to Gs protein, is the receptor that acti-
vates a PKA-dependent signaling pathway upon prostag-
landin exposure. All cells exhibiting an increase of
capsaicin-activated currents upon treatment with a mix-
ture of FSK, IBMX and dbcAMP also showed an increase in
current in the presence of PMA (data not shown), suggest-
ing that both PKA- and PKC-dependent pathways work in
the same cells. To examine how PGE2 changes TRPV1
responsiveness, we measured TRPV1 current in single cells
by applying a range of concentrations of capsaicin in the
absence or presence of PGE2. The currents were normal-
ized to the maximal current produced by 1 µM capsaicin
in each cell. Maximal current in the presence of PGE2 was
almost the same as that in the absence of PGE2. The result-
ant dose-response curves clearly demonstrate that PGE2
enhances capsaicin action on TRPV1 by lowering EC50 val-
ues without altering maximal responses (EC50 from 81.0
nM to 27.6 nM) (Figure 2C). We next examined the effects
of PGE2 on the thermal sensitivity of TRPV1. When tem-
perature ramps were applied to HEK293 cells expressing
both TRPV1 and EP1 in the absence of PGE2, heat-evoked
currents developed at 40.7 ± 0.3°C (n = 8) (Figure 2D). In
contrast, the temperature threshold for TRPV1 activation
was significantly reduced to 30.6 ± 1.1°C in the presence
of PGE2 (n = 8, p < 0.05) (Figure 2D) implying that under
these conditions, TRPV1 could be activated at normal
body temperature. A similar potentiating effect of PGE2
was observed for proton (pH 6.2)-evoked TRPV1 current
responses (0.91 ± 0.06 fold increase, n = 3 for control;
4.47 ± 1.09 fold, n = 7 for PGE2, p < 0.01) (Figure 2E).
These data clearly show that TRPV1 currents evoked by
any of three different stimuli (capsaicin, proton, or heat)
are potentiated or sensitized by PGE2 through EP1 receptor
activation. On the other hand, the temperature threshold
for TRPV1 activation was not changed upon treatment
with a mixture of FSK, IBMX and dbcAMP in HEK293 cells
expressing TRPV1 (40.8 ± 0.8°C, n = 4), suggesting differ-
ent actions on TRPV1 by PKA and PKC.
The signaling pathway downstream of EP1 remains to be
clarified. We have reported that Gq/11-coupled metabo-
tropic receptor activation such as ATP (P2Y), bradykinin
(B2) and proteinase-activated receptor 2 (PAR2) receptors
causes potentiation or sensitization of TRPV1 through the
PKC-dependent phosphorylation of TRPV1 [16-18,25].
Therefore, we examined whether a similar signal transduc-
tion pathway is involved in the regulation of TRPV1
responses through EP1. When calphostin C (Calp.C), a
specific PKC inhibitor, was added to the pipette solution,
the effect of PGE2 was almost completely inhibited (0.92
± 0.15 fold increase, n = 10) (Figure 2F). Similarly, a PKCε
translocation inhibitor (PKCε-I) abolished the potentia-
tion of TRPV1 response by PGE2  (1.11 ± 0.25 fold
increase, n = 11) (Figure 2F). These data suggest that
PGE2-induced potentiation of TRPV1 responsiveness
develops through activation of PKCε. To further confirm
the involvement of PKC-dependent phosphorylation,
PGE2 effects were examined using cells expressing a TRPV1
mutant, S502A/S800A which is insensitive to PKC-
dependent phosphorylation [19]. No potentiation of cap-
saicin-activated currents was observed upon
PGE2treatment of cells expressing S502A/S800A (0.85 ±
0.15 fold increase, n = 5) (Figure 2F), further indicating
the involvement of PKC-dependent phosphorylation.
Since S502 is a PKA-phosphorylation site as well [26], we
examined the effects of treatment with a mixture of FSK,
IBMX and dbcAMP on the capsaicin-activated currents in
cells expressing S502A/S800A. Such treatment failed to
potentiate the capsaicin-activated currents (1.13 ± 0.07
fold increase, n = 10), suggesting that S502 is a substrate
for PKA-dependent phosphorylation of TRPV1 as well.
Sensitization of TRPV1 by EP1 receptors in mouse
To examine the involvement of EP1 in PGE2 (1.5 min)-
induced potentiation of capsaicin-evoked response in
native neurons, we used a specific EP1 agonist, ONO-DI-
004 [27], and a specific EP1 antagonist, ONO-8713 [28],
in mouse DRG neurons. ONO-DI-004 was found to sig-
nificantly increase the capsaicin-activated currents to an
extent similar to that observed with PGE2 (3.36 ± 0.68 foldMolecular Pain 2005, 1:3 http://www.molecularpain.com/content/1/1/3
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PGE2 increases TRPV1 activity through EP1 receptors in a PKC-dependent manner in HEK293 cells Figure 2
PGE2 increases TRPV1 activity through EP1 receptors in a PKC-dependent manner in HEK293 cells. (A) and (B) Treatment 
with PGE2 (1.5 min) potentiates capsaicin-evoked responses in cells expressing rat TRPV1 with mouse EP1 receptors, but not 
with other mouse EP receptors. Cells were pretreated with PGE2 (1 µM) for 1.5 or 6.5 min before second capsaicin (20 nM) 
application. Vh: -60 mV. Currents were normalized as described in Figure 1. * p < 0.05 vs. control (Cont.). Numbers in paren-
thesis indicate cells tested. (C) Capsaicin dose-response curves for TRPV1 activation in the absence (•) and presence (❍ ) of 
extracellular 1 µM PGE2. Currents were normalized to the current maximally activated by 1 µM capsaicin in the absence of 
PGE2. Figure shows averaged data fitted with the Hill equation. EC50 = 81.0 nM and Hill coefficient = 1.33 in the absence of 
PGE2. EC50 = 27.6 nM and Hill coefficient = 1.01 in the presence of PGE2. Data were obtained from 54 different cells. (D) Tem-
perature threshold for TRPV1 activation was reduced in the presence of extracellular PGE2 (1 µM). Representative tempera-
ture-response profiles in the absence (upper) and presence (lower) of PGE2 (left). Temperature threshold for TRPV1 activation 
in the presence of PGE2 (30.6 ± 1.1°C) was significantly lower than that in the absence of PGE2 (40.7 ± 0.3°C) (right). * p < 0.05 
vs. PGE2 (-). Numbers in parenthesis indicate cells tested. (E) Proton-evoked TRPV1 responses were significantly potentiated 
by PGE2 (1 µM). * p < 0.01 vs. PGE2 (-). (F) PKC-dependent pathway is involved in the PGE2 (1 µM, 1.5 min)-induced potentia-
tion of capsaicin-activated currents. In some experiments, calphostin C (Calp. C) (1 µM) or PKCε translocation inhibitor 
(PKCε-I) (200 µM) was included in the pipette solution. Currents were normalized as described in Figure 1. Numbers in paren-
thesis indicate cells tested. * p < 0.05 vs. Cont. Vh: -60 mV.Molecular Pain 2005, 1:3 http://www.molecularpain.com/content/1/1/3
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increase for PGE2, n = 23, p < 0.05 vs. control (Cont.);
3.30 ± 0.68 fold for ONO-DI-004 (EP1 Agon.), n = 9, p <
0.05 vs. Cont.) (Figures 3A left and 3B). Furthermore,
potentiation of the capsaicin-activated currents by PGE2
was inhibited in the presence of ONO-8713 (EP1 Antg.,
1.00 ± 0.17 fold increase, n = 8) (Figures 3A right and 3B).
These results indicate that PGE2 (1.5 min)-induced poten-
tiation of the capsaicin-activated current responses occurs
through EP1 receptors in DRG neurons. To confirm the
involvement of PKC-dependent events downstream of
PGE2 effects in DRG neurons, we first examined the effects
of a specific phospholipase C (PLC) inhibitor, U73122 (3
µM). PGE2-induced potentiation of capsaicin-activated
current was significantly diminished in the presence of
U73122 while control U73343 exhibited no such effects
(0.73 ± 0.11 fold increase, n = 8 for U73343; 3.40 ± 1.11
EP1 receptor involvement in PGE2 (1.5 min)-induced potentiation of capsaicin-activated currents in mouse DRG neurons Figure 3
EP1 receptor involvement in PGE2 (1.5 min)-induced potentiation of capsaicin-activated currents in mouse DRG neurons. (A) 
Representative traces of potentiation of capsaicin-activated currents by a specific EP1 agonist, ONO-DI-004 (10 µM, 1.5 min), 
and reverse of the PGE2 (1.5 min)-induced potentiation by a specific EP1 antagonist, ONO-8713 (1 µM). Vh: -60 mV. (B) Effects 
of PGE2 (1 µM), ONO-DI-004 (EP1 Agon., 10 µM), PGE2 plus ONO-8713 (EP1 Antg., 1 µM), PGE2 plus U73122 (3 µM), PGE2 
plus U73343 (3 µM), phorbol 12-myristate 13-acetate (PMA, 100 nM) or PGE2 plus PKCε-I (200 µM) on capsaicin-activated 
currents in DRG neurons from wild type (EP1
+/+) mice, and effects of PGE2 on capsaicin-activated currents in DRG neurons 
from EP1
-/- mice. Currents are normalized as described in Fig. 1. * p < 0.05 vs. Cont., + p < 0.05 vs. U73343. Numbers in paren-
thesis indicate cells tested. (C) Co-expression of TRPV1 (green) and PKCε (blue) in mouse DRG. Arrowheads indicate neu-
rons positive for TRPV1 but not for PKCε. Arrows indicate neurons positive for both TRPV1 and PKCε (light blue). Bar, 100 
µm.Molecular Pain 2005, 1:3 http://www.molecularpain.com/content/1/1/3
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fold, n = 8 for U73433, p < 0.05) (Figure 3B). Further-
more, PGE2 failed to potentiate the capsaicin-activated
currents when PKCε-I was included in the pipette solution
(0.86 ± 0.09 fold increase, n = 12) (Figure 3B). A robust
potentiating effect of phorbol 12-myristate 13-acetate
(PMA, 100 nM) also supported the involvement of PKC-
dependent events (16.36 ± 3.68 fold increase, n = 11, p <
0.05) (Figure 3B). To further confirm the involvement of
EP1 receptors, DRG neurons of EP1 deficient mice (EP1
-/-)
were subjected to patch-clamp analysis. PGE2 failed to
potentiate capsaicin-activated currents in the DRG neu-
rons from EP1
-/- mice (1.45 ± 0.70 fold increase, n = 10)
(Figure 3B). Functional interaction of PKCε with TRPV1
prompted us to examine the expression of the two pro-
teins in mouse DRG. Three hundred seventy eight out of
541 TRPV1 positive neurons (69.9 %) were stained with
anti-PKCε antibody, supporting the TRPV1 activation
pathway through PKCε (Figure 3C).
We next investigated the involvement of EP1 receptors in
PGE2-induced thermal hyperalgesia at the behavioral
level. PGE2-induced thermal hyperalgesia was signifi-
cantly diminished at 15 to 45 min after injection in EP1
-/-
mice (Figure 4A), relative to that observed in wild type
mice. The involvement of EP1  receptors in the PGE2-
induced hypersensitivity was supported by another
behavioral analysis in which PGE2 caused less reduction
of paw withdrawal latency in wild type mice pretreated
with a specific EP1 antagonist (500 pmol/ 20 µL) than in
vehicle control (Figure 4A). These results suggest that a
PKC-dependent pathway downstream of EP1 activation is
mainly involved in PGE2-induced thermal hyperalgesia.
We have hypothesized that the potentiation of TRPV1
activity by several inflammatory mediators could repre-
sent one important mechanism underlying acute inflam-
matory pain sensation. To prove the accuracy of this
hypothesis, we investigated the involvement of EP1 in
inflammatory pain-related responses using mustard oil
which is known to cause inflammation [29,30]. Topical
application of mustard oil induced clear thermal hyperal-
gesia (Figure 4B). The mustard oil-induced thermal hyper-
algesia was significantly reduced both in TRPV1-/- mice
and EP1
-/- mice. Thus, these data show that EP1 contributes
to inflammatory nociception in mice and support the
hypothesis.
Interaction between TRPV1 and EP1 receptors in a behavioral level Figure 4
Interaction between TRPV1 and EP1 receptors in a behavioral level. (A) PGE2-induced thermal hyperalgesia in wild type mice 
with (, n = 6) or without (❍ , n = 6) pretreatment (ONO-8713, 500 pmol/ 20 µL), or in EP1
-/- mice (•, n = 6). * p < 0.05 vs. wild 
type mice. (B) 10% Mustard oil-induced thermal hyperalgesia in wild type mice (❍ , n = 12), TRPV1-/- mice (Њ, n = 6) or EP1
-/- 
mice (•, n = 6). * p < 0.05, ** p < 0.01 vs. wild type mice.Molecular Pain 2005, 1:3 http://www.molecularpain.com/content/1/1/3
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PGI2 causes potentiation or sensitization of TRPV1 through mainly through PKC activation Figure 5
PGI2 causes potentiation or sensitization of TRPV1 through mainly through PKC activation. (A) Representative traces of 
potentiation of capsaicin-activated currents by PGI2 (1000 nM, 1.5 min), a specific IP agonist, ONO-54918-07 (1.5 min) or PGI2 
(100 nM, 6.5 min), but not by PGI2 (100 nM, 1.5 min) in mouse DRG neurons. Vh: -60 mV. (B) Effects of treatments (1.5 or 6.5 
min) with PGI2 (100 or 1000 nM), ONO-54918-07 (IP Agon., 100 nM), PGI2 (1000 nM) plus ONO-8713 (EP1 Antg., 1 µM), PGI2 
(1000 nM) plus U73122 (3 µM), PGI2 (1000 nM) plus U73343 (3 µM) or PGI2 (1000 nM) plus PKCε-I (200 µM) on capsaicin-
activated currents in DRG neurons from wild type (IP+/+) mice, and effects of PGI2 on capsaicin-activated currents in DRG neu-
rons from IP-deficient (IP-/-) mice. Currents are normalized as described in Figure 1. * p < 0.05 vs. Cont. ++ p < 0.01 vs. 
U73343, # p < 0.05, ## p < 0.01 vs. PGI2 (1000 nM, 1.5 min) in DRG neurons from IP+/+ mice. Numbers in parenthesis indicate 
cells tested. (C) A representative trace of potentiation of capsaicin-activated currents by PGI2 (1000 nM, 1.5 min) in HEK293 
cells expressing both TRPV1 and IP. Vh: -60 mV. (D) Effects of treatments (1.5 or 6.5 min) with PGI2 (100 or 1000 nM) or PGI2 
(1000 nM) plus calphostin C (Calp. C, 1 µM) on capsaicin-activated currents in HEK293 cells expressing rat wild type TRPV1 or 
S502A/S800A mutant with IP. Currents are normalized as described in Figure 1. * p < 0.05 vs. Cont. (E) Temperature thresh-
old for TRPV1 activation in the presence of PGI2 (32.2 ± 1.2°C) was significantly lower than that in the absence of PGI2 (38.2 ± 
0.5°C) in HEK293 cells expressing rat TRPV1 and IP. * p < 0.01 vs. PGI2 (-).Molecular Pain 2005, 1:3 http://www.molecularpain.com/content/1/1/3
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Sensitization of TRPV1 by IP receptors
In order to determine whether the observed responses are
specific to PGE2, we extended our analysis to PGI2 whose
receptor has been reported to be involved in nociception
[8]. We first examined the effects of PGI2 on capsaicin-acti-
vated currents in mouse DRG neurons. PGI2 pretreatment
(1000 nM, 1.5 min) potentiated capsaicin (100 nM)-acti-
vated currents (3.23 ± 0.55 fold increase, n = 14 or 0.78 ±
0.08 fold, n = 5 with or without (Cont.) PGI2, respectively;
p < 0.05) whereas at 100 nM, PGI2 (1.5 min) showed no
such effects (1.24 ± 0.22 fold, n = 11) (Figures. 5A and
5B). On the other hand, long (6.5 min) treatment with
PGI2 (100 nM) caused significant potentiation of capsai-
cin-activated currents as in the treatment with a mixture of
FSK, IBMX and dbcAMP (2.06 ± 0.54 fold increase, n = 11,
p < 0.05 vs. Cont.) (Figures 5A and 5B). The potentiation
effects of PGI2  appear to occur through IP receptors
because a specific IP agonist, ONO-54918-07 (100 nM)
[31] caused similar potentiation of capsaicin-activated
currents (Agon., 3.71 ± 0.81 fold increase, n = 9, p < 0.05
vs. Cont.) (Figures 5A and 5B) although PGI2 is known to
cross react with some EP receptors [2]. The fact that a spe-
cific EP1  antagonist, ONO-8713 failed to prevent the
PGI2-induced potentiation (+EP1 Antg., 3.55 ± 1.17 fold
increase, n = 6) (Figure 5B) further suggests the involve-
ment of IP receptors in the potentiation process. The
involvement of IP receptors in the PGI2-induced potenti-
ation of capsaicin-activated currents was further sup-
ported by the ineffectiveness of PGI2 on DRG neurons
from IP-deficient mice (IP-/-) (1.25 ± 0.16 fold increase, n
= 9, p < 0.01 vs. 1000 nM of PGI2) (Figure 5B). It has been
reported that low concentrations of PGI2 stimulate Gs
protein coupled to IP receptors whereas high concentra-
tions of PGI2 stimulate not only Gs but also Gq [32]. This
property might explain the dose-dependent effects of PGI2
on capsaicin-activated currents: PKC-dependent sensitiza-
tion of TRPV1 occurs downstream of Gq-coupled IP recep-
tor activation at high concentrations (1000 nM) of PGI2
(1.5 min) while long (6.5 min) treatment with low con-
centrations (100 nM) of PGI2  causes potentiation of
TRPV1 activity through Gs activation. To test this hypoth-
esis, PGI2 (1.5 min)-induced potentiation of capsaicin-
activated currents was examined in the presence of
U73122. When U73122 was included in the pipette solu-
tion, PGI2 (1.5 min) failed to potentiate the currents
whereas U73343 exhibited no such effects, indicating the
involvement of PLC activation in the potentiating process
(0.97 ± 0.40 fold increase, n = 9 for U73122, 2.58 ± 0.66
fold, n = 5 for U73343, p < 0.05) (Figure 5B). Further-
more, PKCε-I included in the pipette solution almost
completely blocked the PGI2 (1000 nM)-induced potenti-
ation (1.49 ± 0.60 fold increase, n = 14), suggesting the
involvement of PKCε-dependent regulation mechanism
(Figure 5B).
Dose-dependent PGI2 (1.5 min)-induced potentiation of
capsaicin-activated currents was also observed in HEK293
cells expressing TRPV1 and IP receptors (0.90 ± 0.04 fold
increase, n = 9 without PGI2 (Cont.); 0.68 ± 0.08 fold, n =
12 with 100 nM of PGI2; 0.75 ± 0.07 fold, n = 6 with 300
nM PGI2, 4.96 ± 1.36 fold, n = 8 with 1000 nM of PGI2, p
< 0.01 vs. Cont.) (Figures 5C and 5D, and data not
shown). Calp. C blocked PGI2-induced potentiation of
TRPV1 currents (0.75 ± 0.15 fold increase, n = 6) (Figure
5D). Furthermore, PGI2 (1000 nM) failed to potentiate
capsaicin-activated currents in HEK293 cells expressing
the S502/S800 mutant (0.80 ± 0.05 fold, n = 6) (Figure
5D). Long (6.5 min) treatment with PGI2  (100 nM)
caused an increase in capsaicin-activated currents in 4 out
of 6 cells, as did long treatment with a mixture of FSK,
IBMX and dbcAMP in HEK293 cells expressing TRPV1
(3.19 ± 1.45 fold increase, n = 6, p = 0.16). These results
suggest that a mechanism involving PKC is predomi-
nantly involved in the regulation of TRPV1 activity during
short treatment with PGI2 although both PKA-dependent
and PKC-dependent pathways may contribute. The tem-
perature threshold for TRPV1 activation was significantly
reduced (from 38.2 ± 0.5°C, n = 5 to 32.2 ± 1.2°C, n = 5)
in the presence of PGI2, suggesting the possibility that IP
receptor activation can cause nociception at body temper-
ature (Figure 5E). Finally, PGI2-induced thermal hyperal-
Interaction between TRPV1 and IP receptors at a behavioral  level Figure 6
Interaction between TRPV1 and IP receptors at a behavioral 
level. PGI2-induced thermal hyperalgesia in wild type mice 
(❍ , n = 6), TRPV1-/- mice (Њ, n = 6) or IP-/- mice (•, n = 6). 
Thermal hyperalgesia by intraplantar PGI2 (500 pmol/ 20 µL) 
injection was significantly diminished in TRPV1-/- mice and IP-/
- mice. * p < 0.05, ** p < 0.01 vs. wild type mice.Molecular Pain 2005, 1:3 http://www.molecularpain.com/content/1/1/3
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gesia observed in wild type mice disappeared almost
completely in both TRPV1-deficient (TRPV1-/-) mice and
IP-deficient (IP-/-) mice, suggesting that the functional
interaction of TRPV1 with IP causes thermal hyperalgesia
at the behavioral level (Figure 6).
Discussion
The data presented herein demonstrate that TRPV1 is
essential for the development of thermal hyperalgesia in
vivo induced by two major inflammation-associated pros-
taglandins, PGE2 and PGI2, and that TRPV1 and EP1 or IP
receptors can functionally interact, mainly through a PKC-
dependent pathway. The temperature threshold for
TRPV1 activation is reduced below 35°C in the presence
of prostaglandins, so that TRPV1 can be activated at nor-
mal body temperature, possibly leading to spontaneous
pain sensation. This interaction might be one important
underlying mechanism for the well-recognized peripheral
nociceptive actions of PGE2 or PGI2 in the context of
inflammation. In the present study, 1 µM PGE2 or PGI2
was found to potentiate or sensitize TRPV1 activity. It is
not well known how much PGE2 or PGI2  is released
locally at the site of inflammation. However, more than
micromolar-order concentrations of PGE2 and PGI2 have
been reported to be synthesized by macrophages upon
lipopolysacharide (LPS) stimulation [33,34], suggesting
that 1 µM is an attainable concentration in the context of
inflammation. It has been previously reported that EP1 is
coupled to intracellular Ca2+ mobilization in CHO cells
[35]. However, the transduction events downstream of
EP1 signaling have been unclear. Together with a report
suggesting the possible coupling of EP1 with Gq/11-protein
[36], our data indicate that EP1 receptors activate a PKC-
dependent signal transduction pathway.
There has been extensive work demonstrating the activa-
tion of a PKA-dependent pathway by PGE2 that influences
capsaicin- or heat-mediated actions in rat sensory neurons
[20-22,37,38] as well as interactions between cloned
TRPV1 and PKA [26,39-42]. These results suggest that PKA
plays a pivotal role in the development of hyperalgesia
and inflammation by prostaglandins. In our experiments
using mouse DRG neurons and HEK293 cells expressing
TRPV1, a PKC-dependent pathway was found to be pre-
dominantly involved in both PGE2 (1.5 min)- and PGI2
(1.5 min)-induced responses. The reason that there has
been no study describing the involvement of a PKC-
dependent pathway in the regulation of TRPV1 following
prostaglandin receptor activation is not clear. In the
present study, it was found that both PKA- and PKC-
dependent pathways are involved downstream of prostag-
landin actions on TRPV1 although the PKC-dependent
one appears to predominate. A PKA-dependent pathway
took a relatively long time to exert its potentiating effects
on TRPV1 activity, suggesting some difference between
PKA- and PKC-dependent phosphorylation of TRPV1.
Indeed, Bhave et al. treated cells with 8-Br-cAMP for 30
min to inhibit TRPV1 desensitization through phosphor-
ylation [39], and significant potentiation of capsaicin-
activated currents in rat DRG neurons was observed upon
prolonged (greater than 10 min) exposure to PGE2 [21].
Furthermore, there is a report describing the ineffective-
ness of PKA stimulation on TRPV1 currents in Xenopus
oocytes treated with 8-Br-cAMP and IBMX for relatively
short periods [24]. Both PKA-dependent and PKC-
dependent pathways might work in concert in native cells.
Patch-clamp recordings in the previous studies were per-
formed in the Ca2+-containing solutions, whereas we did
all of our experiments under Ca2+-free conditions, to
avoid Ca2+-dependent TRPV1 desensitization [43]. Poten-
tiation of capsaicin-activated currents by PGE2  was
observed in embryonic rat DRG neurons [21] while we
used adult mouse DRG neurons. Furthermore, potentia-
tion of heat-activated currents [26], inhibition of desensi-
tization of capsaicin-activated currents [39,41,44] or
anandamide-induced cytosolic Ca2+ increase [40] but not
potentiation of capsaicin-activated current response were
examined in the previous studies investigating the
involvement of PKA-dependent pathway in TRPV1 activ-
ity. Thus, difference in experimental conditions or readout
might also account for the different outcomes. The physi-
ological relevance of the two different pathways down-
stream of prostaglandin exposure remains to be
elucidated. The fact that only PKC activation leads to the
reduction of temperature threshold for TRPV1 activation
might be pertinent to this issue. Disruption of interaction
between phosphatidylinositol-4, 5-bisphosphate (PIP2)
and TRPV1 has also been reported to be involved in the
sensitization of TRPV1 downstream of PLC activation
[45,46]. In our study, however, both PGE2- and PGI2-
induced potentiation of TRPV1 activity was completely
inhibited by treatments with two kinds of PKC inhibitors.
Thus, we believe that a PKC-dependent pathway is pre-
dominantly involved in the PGE2- and PGI2-induced
potentiation or sensitization of TRPV1 activity in mice.
The inhibition of PGE2-induced thermal hyperalgesia
observed in EP1
-/- mice, while significant, was not very
robust, compared with that in TRPV1-/- mice (Figure 4).
Other pathways, most likely including one involving PKA,
might account for the residual component. Further, inhi-
bition of mustard oil-induced thermal hyperalgesia
observed in TRPV1-/- or EP1
-/- mice might seem not to be
robust or dramatic (Figure 4). Since many inflammatory
factors activating PLC-coupled receptors are involved in
the inflammatory response [47,48]. In such a complicated
environment, thermal hyperalgesia was significantly
diminished in TRPV1-/- mice or EP1
-/- mice albeit at a few
time points, suggesting the importance of the two mole-
cules in the context of inflammatory pain sensation.Molecular Pain 2005, 1:3 http://www.molecularpain.com/content/1/1/3
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Given the fact that one of the final targets of both PGE2
and PGI2 is TRPV1 as shown in our study, compounds act-
ing on EP1, IP or TRPV1, or interfering with their interac-
tion could prove useful in the treatment of pain and
inflammation.
Conclusions
Potentiation or sensitization of TRPV1 activity through
EP1  or IP activation, mainly through PKC- and PKA-
dependent mechanisms, might be important mechanism




Male C57BL/6-strain mice (4 weeks, SLC, Shizuoka,
Japan), EP1-deficient mice (4 weeks, from Dr. Narumiya),
IP-deficient mice (4 weeks, from Dr. Narumiya) or
TRPV1-deficient mice (4 weeks, from Dr. Julius, UCSF)
were used. They were housed in a controlled environment
(12 h light/dark cycle, room temperature 22–24°C, 50–
60% relative humidity) with free access to food and water.
All procedures involving the care and use of mice were car-
ried out in accordance with institutional (Mie University)
guidelines and the National Institute of Health guide for
the care and use of laboratory animals.
Behavioral study
Thermal nociceptive threshold was assessed using the paw
withdrawal test. Mice were placed in a transparent Perspex
box on a thin glass platform (Plantar test, Ugo Basile,
Italy). They were injected intraplantarly with PGE2 (500
pmol/ 20 µL, Sigma) with or without ONO-8713 (500
pmol/ 20 µL), or with PGI2 (500 pmol/ 20 µL, Sigma), or
applied topically to the plantar surface of right hind paw
with 10% mustard oil (Sigma) (diluted with mineral oil),
and the paw withdrawal latency to radiant heat applied to
the plantar surface of hind paw was measured as the time
from onset of the radiant heat to the withdrawal of the
mouse hind paw.
Cell culture
Human embryonic kidney-derived (HEK293) cells were
maintained in Dulbecco's modified Eagle's medium (Inv-
itrogen; supplemented with 10% fetal bovine serum, pen-
icillin, streptomycin and L-glutamine) and transfected
with 0.5 µg of rat TRPV1 cDNA and 0.5 µg of mouse EP or
IP receptor cDNAs (EP1, EP2, EP3α, EP3β, EP3γ, EP4 or IP)
using Lipofectamine Plus Reagent (Invitrogen). Primary
cultures prepared from adult C57BL/6-strain mice, EP1-
deficient mice or IP-deficient mice dorsal root ganglion
(DRG) neurons were incubated in medium containing
nerve growth factor (Sigma, 100 ng/ml).
Electrophysiology
Whole-cell patch-clamp recordings were performed 1 day
after transfection to HEK293 cells or dissociation of the
DRG neurons. Standard bath solution contained 140 mM
NaCl, 5 mM KCl, 2 mM MgCl2, 5 mM EGTA, 10 mM
HEPES, 10 mM glucose, pH7.4 (adjusted with NaOH).
Pipette solution contained 140 mM KCl, 5 mM EGTA, 10
mM HEPES, pH7.4 (adjusted with KOH). All patch-clamp
experiments were performed at room temperature
(22°C). Thermal stimulation was applied by increasing
the bath temperature at a rate of 1.0°C/sec with a pre-
heated solution. When the heat-activated currents started
to inactivate, the preheated solution was changed to a
22°C one. Chamber temperature was monitored with a
thermocouple placed within 100 µm of the patch-
clamped cell. For this analysis, heat-evoked current
responses were compared between different cells, rather
than within the same cell, because repetitive heat-evoked
currents show significant desensitization even in the
absence of extracellular Ca2+ [13] and because the thermal
sensitivity of TRPV1 increases with repeated heat applica-
tion [49]. Threshold temperature for activation was
defined as the intersection where two lines approximating
the stable baseline current and the clearly increasing tem-
perature-dependent current cross in the temperature-
response profile. The sensitivity of DRG neurons to capsa-
icin is slightly lower than that of TRPV1-transfected
HEK293 cells as previously reported [18,50]. Therefore,
we applied capsaicin at 100 nM to DRG neurons and at 20
nM to HEK293 cells.
cAMP measurement
Intracellular cAMP level was examined using 'cAMP
Biotrak Enzymeimmunoassay System' according to the
manufacture's direction (Amersham Biosciences). In
brief, intracellular cAMP released upon membrane
hydrolysis of treated cells (10,000 cells/ well) after stimu-
lation (90 sec) was measured based on competition
between unlabelled cAMP and a fix quantity of
Peroxidase-labeled cAMP for a limited number of the
binding sites on a cAMP specific antibody.
Immunostaining
DRG was removed from male C57BL/6-strain mice and
frozen in liquid nitrogen, and the frozen tissue was cut on
a cryostat at a 10 µm thickness. The sections were incu-
bated with the rabbit anti-rat TRPV1 polyclonal antibody
(1: 500; Oncogene) and anti-rat PKCε monoclonal
antibody (1: 250; Transduction lab) at 4°C for 2 days.
Slides with the section were washed with PBS, followed by
incubation with Alexa 488-conjugated goat anti-rabbit
IgG (1: 700, Molecular Probes), Alexa 350-conjugated
anti-mouse IgG (1: 500, Molecular Probes) and Texas
Red-phalloidin (1: 500, Molecular Probes). Images were
obtained using an Olympus fluorescent microscope withMolecular Pain 2005, 1:3 http://www.molecularpain.com/content/1/1/3
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a cooled-CCD camera (ORCA-ER, Hamamatsu Photon-
ics) and IP-Lab Image software (Scanalytics Inc.).
Chemicals
ONO-DI-004, ONO-8713 and ONO-54918-07 were
obtained from Ono Pharmaceutical Co., Ltd (Osaka,
Japan). Calphostin C, phorbol 12-myristate 13-acetate,
forskolin, 3-isobutyl-1-methylxanthine, dibutyryl-cAMP,
isoproterenol, U73122 and U73343 were from Sigma,
and PKCε translocation inhibitor was from Calbiochem.
Statistics
Values are shown as the mean ± S.E. and data are analyzed
using an unpaired t test. P values of < 0.05 were consid-
ered significant.
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